Biomarker lifts a secret of old age05.09.2016 – Why do people grow old? Italian researchers took a close look at centenarians and found that low levels of the peptide hormone Adrenomedullin may significantly contribute towards good microcirculation … more ➔
mAb ray of hope for Alzheimers01.09.2016 – The causes of Alzheimer’s disease are still largely unknown. But now, an antibody developed by the University of Zurich has significantly reduced the brain amyloid plaques typical for Alzheimers … more ➔
Ferring bags slipped disk pain drug30.08.2016 – Swiss biopharma company Ferring has acquired the exclusive development and commercialisation rights to Seikagakus Phase III chemonucleolytic leg pain treatment for €85m. more ➔
Phase III washout for AdociaAdocia said it would discontinue its diabetic foot ulcer programme after its lead product BioChaperone PDGF disappointed in Phase III. The French company will turn the focus on its earlier-stage products. more ➔
AZ unloads antibiotics to Pfizer24.08.2016 – Pharma major Pfizer is putting the cherry on top of its multi-billion-dollar takeover of Medivation with the acquisition of AstraZenecas antibiotics for a cool US$1.5bn. With the divestment, … more ➔
€87m for Cambridge Cluster fund23.08.2016 – Cambridge University-allied investor Cambridge Innovation Capital has raised £75m (€87m) to reinvest in technology and healthcare companies. Among the backers were Woodford Investment … more ➔
Priority review for Genmabs Darzalex?19.08.2016 – Together with partner Johnson & Johnson, Danish biotech Genmab is now one step closer to FDA approval with its combination treatment for multiple myeloma after its submission of a supplemental … more ➔
Post-Brexit EU funding securedPhilip Hammond, the UKS chancellor has announced the government will guarantee funding for EU-backed "structural and investment fund" projects whose timelines extend beyond the UKs departure … more ➔
Epigenomics considers US listingBack in April, the American FDA gave the green light for the colorectal cancer-screening test Epi procolon. Now Berlin-based diagnostics specialist Epigenomics is considering a secondary listing in the … more ➔
Genmab in HIV antibody dealDanish Genmab AS has granted Gilead Sciences license to use its DuoBody technology platform to develop bispecific antibodies for the treatment of HIV. The deal is worth up to €252m. more ➔
